Publiziert in: Marktpuls, Unternehmen
Frei

Dietmar Bettio appointed to the Executive Committee of Nobel Biocare Montag, 16. Dezember 2013 - 07:00

Media release

ZURICH, SWITZERLAND – DECEMBER 16, 2013

Dietmar Bettio appointed to the Executive Committee of Nobel Biocare

Nobel Biocare announced today that its Chief Information Officer (CIO) Dietmar Bettio (formerly Böhm), has been appointed as Executive Vice President to the Nobel Biocare Executive Committee effective January 1, 2014. Dietmar Bettio (46) joined Nobel Biocare in January of 2012 and has significantly contributed to strengthen and optimize the IT processes and business alignment. Prior to joining Nobel Biocare he gained senior management experience in Sonova, Forbo International and Mathys Medical.

Richard Laube, CEO of Nobel Biocare: "I am pleased to welcome Dietmar Bettio into the Executive Committee. He has proven strong skills in process management and will help us further in becoming more efficient and effective in serving our customers."

Nobel Biocare (SIX Swiss Exchange: NOBN) is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (Creos®). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 580.5 million in 2012. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare’s management. When used in this media release, words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” and “project” are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.

Further information is available from:

Süha Demokan
Investor & Corporate Relations
Tel: +41 43 211 42 30, +41 79 430 81 46
suha.demokan@nobelbiocare.com